Literature DB >> 28625123

Role of the N-acetylation polymorphism in solithromycin metabolism.

David W Hein1, Mark A Doll1.   

Abstract

AIM: Solithromycin is a new macrolide antibiotic for the potential treatment of bacterial pneumonia. MATERIALS &
METHODS: Solithromycin N-acetylation by human NAT1 and NAT2 was investigated following recombinant expression in yeast and in cryopreserved human hepatocytes from rapid, intermediate and slow acetylators.
RESULTS: Solithromycin exhibited over twofold higher affinity for recombinant human NAT2 than NAT1. Apparent maximum velocities for the N-acetylation of solithromycin catalyzed by the NAT2 allozyme associated with rapid acetylators were significantly (p < 0.01) higher than by the NAT2 allozymes associated with slow acetylators. Robust gene dose responses (rapid>intermediate>slow acetylators) were exhibited in cryopreserved human hepatocytes in situ following incubation with 100 μM solithromycin.
CONCLUSION: Solithromycin is N-acetylated by human NAT1 and NAT2 and the role of the NAT2 acetylation polymorphism on solithromycin metabolism may be concentration dependent.

Entities:  

Keywords:  N-acetyltransferase 2; acetylation polymorphism; cryopreserved human hepatocytes; solithromycin

Mesh:

Substances:

Year:  2017        PMID: 28625123      PMCID: PMC5704091          DOI: 10.2217/pgs-2017-0045

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  31 in total

1.  Comprehensive human NAT2 genotype method using single nucleotide polymorphism-specific polymerase chain reaction primers and fluorogenic probes.

Authors:  M A Doll; D W Hein
Journal:  Anal Biochem       Date:  2001-01-01       Impact factor: 3.365

2.  Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.

Authors:  Jotam G Pasipanodya; Shashikant Srivastava; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2012-03-30       Impact factor: 9.079

3.  Human acetyltransferase polymorphisms.

Authors:  D M Grant; N C Hughes; S A Janezic; G H Goodfellow; H J Chen; A Gaedigk; V L Yu; R Grewal
Journal:  Mutat Res       Date:  1997-05-12       Impact factor: 2.433

4.  Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype.

Authors:  M A Leff; A J Fretland; M A Doll; D W Hein
Journal:  J Biol Chem       Date:  1999-12-03       Impact factor: 5.157

5.  In vitro activity of solithromycin and its metabolites, CEM-214 and N-acetyl-CEM-101, against 100 clinical Ureaplasma spp. isolates compared with azithromycin.

Authors:  Lucy L Furfaro; O Brad Spiller; Jeffrey A Keelan; Matthew S Payne
Journal:  Int J Antimicrob Agents       Date:  2015-06-19       Impact factor: 5.283

6.  Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).

Authors:  Carlos M Barrera; Analia Mykietiuk; Hristo Metev; Mimi Floarea Nitu; Najumuddin Karimjee; Pablo Alexis Doreski; Ismail Mitha; Cristina Mihaela Tanaseanu; Joseph McDermott Molina; Yuri Antonovsky; Dirkie Johanna Van Rensburg; Brian H Rowe; Jose Flores-Figueroa; Barbara Rewerska; Kay Clark; Kara Keedy; Amanda Sheets; Drusilla Scott; Gary Horwith; Anita F Das; Brian Jamieson; Prabhavathi Fernandes; David Oldach
Journal:  Lancet Infect Dis       Date:  2016-02-05       Impact factor: 25.071

7.  Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1.

Authors:  A J Fretland; M A Doll; M A Leff; D W Hein
Journal:  Pharmacogenetics       Date:  2001-08

Review 8.  PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.

Authors:  Ellen M McDonagh; Sotiria Boukouvala; Eleni Aklillu; David W Hein; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-08       Impact factor: 2.089

9.  Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions.

Authors:  D W Hein; M A Doll; T D Rustan; R J Ferguson
Journal:  Cancer Res       Date:  1995-08-15       Impact factor: 12.701

10.  NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.

Authors:  Junichi Azuma; Masako Ohno; Ryuji Kubota; Soichiro Yokota; Takayuki Nagai; Kazunari Tsuyuguchi; Yasuhisa Okuda; Tetsuya Takashima; Sayaka Kamimura; Yasushi Fujio; Ichiro Kawase
Journal:  Eur J Clin Pharmacol       Date:  2012-11-14       Impact factor: 2.953

View more
  3 in total

1.  N-acetyltransferase 2 acetylator genotype-dependent N-acetylation and toxicity of the arylamine carcinogen β-naphthylamine in cryopreserved human hepatocytes.

Authors:  Mariam R Habil; Raúl A Salazar-González; Mark A Doll; David W Hein
Journal:  Arch Toxicol       Date:  2022-09-16       Impact factor: 6.168

2.  N-Acetyltransferase 2 Genotype-Dependent N-Acetylation of Hydralazine in Human Hepatocytes.

Authors:  Cecily E Allen; Mark A Doll; David W Hein
Journal:  Drug Metab Dispos       Date:  2017-10-10       Impact factor: 3.922

3.  Arylamine N-acetyltransferase 2 genotype-dependent N-acetylation of isoniazid in cryopreserved human hepatocytes.

Authors:  Mark A Doll; Raúl A Salazar-González; Srineil Bodduluri; David W Hein
Journal:  Acta Pharm Sin B       Date:  2017-06-07       Impact factor: 11.413

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.